Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help doctors find CNS metastases and plan treatment.

PURPOSE: This randomized clinical trial is studying how well MRI finds CNS metastases in women with stage IV breast cancer.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jules Bordet Institute
• Treatments: Trastuzumab

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed breast cancer

• Stage IV disease

• HER2/neu-overexpression (3+ by immunohistochemistry AND/OR gene amplification by fluorescence in situ hybridization)

• Undergoing treatment with trastuzumab (Herceptin®) (alone or together with chemotherapy) once weekly or 3 times weekly AND has achieved responding or stable disease for ≥ 12 weeks

• No CNS metastases (i.e., brain parenchymal lesions and/or leptomeningeal carcinomatosis)

• No uncontrolled metastatic disease at study entry

• Hormone receptor status

• Not specified

PATIENT CHARACTERISTICS:

• Female

• Menopausal status not specified

• Karnofsky performance status 70-100%

• No contraindication to MRI scan

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics